Diabetes

OBESITY & METABOLIC DISORDERS

Obesity and metabolism related disorders are key therapeutic areas that have attracted global attention over recent years. Porsolt has in place a comprehensive range of models for obesity, impaired glucose tolerance, and diabetes to assist with the development of novel therapeutic agents for the treatment and reduction of risk factors associated with metabolic diseases.

Diabetes

Porsolt offers in vitro models and several in vivo models for screening and testing the therapeutic potential of novel drugs to treat diabetes.

Animal models: 

ob/ob mice, db/db mice, Zucker Diabetic Fatty (ZDF) rats, Streptozotocin (STZ)-induced diabetes, Alloxan-induced diabetes …

Assessments:

Body weight, Food/caloric intake, Glucose/Insulin levels, Glucose/Insulin tolerance tests, Metabolic biomarkers,…

Portfolio

in vitro model

NEW!   Glucose stimulated insulin secretion 

 Rat insulinoma INS-1 cells PF 7.2
Chemically-induced animal models
Streptozotocin (STZ)-induced diabetes (rats or mice)   Type 1 diabetes, single injection  of streptozotocin 
Alloxan-induced diabetes (rats) Type 1 diabetes, single injection of alloxan 
HFD/STZ-induced diabetes (rats) Type 2 diabetes

Genetic animal models
ob/ob mice 

Leptin-deficient mouse: obesity, Type 2 diabetes

db/db mice

Leptin-deficient mouse: obesity, Type 2 diabetes 
Zucker Diabetic Fatty (ZDF) rats Type 2 diabetes, glucose intolerance, hyperinsulinemia...

Assessments
Oral glucose tolerance test (OGTT)
HOMA-IR, QUICKI and ISI calculation		 Mouse – Rat MET 12
Intravenous glucose tolerance test (IVGTT) Rat MET 1
Insulin tolerance test (ITT)  Mouse –Rat MET 2

and Body weight gain | Food, water or caloric intake

Biochemistry

HOMA-IR, QUICKI and ISI calculation

Lipid panel (Triglycerides, Cholesterol, Free Fatty Acids,…)

Liver function panel (AminoTransferases, Alkaline Phosphatase, Bilirubin)

Renal function panel (Creatinine, Electrolytes,…)

Metabolic biomarkers (Adiponectin, Leptin, Glucagon,…)

Organ & Tissue collection

STZ-Induced Diabetes model -Type I diabetes model

Sprague Dawley rats fed a standard diet (SD) and given a single administration of streptozotocin (STZ 45 mg/kg). Effects of subchronic treatment (from Day 24 to Day 28 post STZ) in selected diabetic rats.

Basal glycemia

OGTT at Day 28

> Additional parameters: plasma insulin, urinary volume, glomerular filtration rate, food/water intake

> References: Metformin, Insulin

Zucker Diabetic Fatty (ZDF) Rats - Type II diabetes model

The diabetic profile of ZDF rats, 10-16 weeks of age, is characterized by increased body weight, hyperglycemia, hyperinsulinemia, glucose intolerance increasing in time, hyperphagia, polydipsia, polyuria, decrease in glomerular filtration rate (GFR), high levels of cholesterol and triglycerides.

Basal blood glucose and plasma insulin in ZDF rats at 10 and 16 weeks old

OGTT in ZDF rats aged 10 and 16 weeks old: effects of sitagliptin